The FDA said the shortage of Novo Nordisk's weight-loss drugs Wegovy and Ozempic is resolved. The move could limit cheaper compounded versions ...

The third-place slot marked another return to form. Novo Nordisk’s Wegovy reclaimed the seat it held in December, backed by ...

With semaglutide shortages in the rearview, Novo Nordisk is doubling down on marketing efforts for its GLP-1 drugs.

Introducing Hot Shots, a series that examines how Ozempic and other GLP-1 drugs have transformed the way we think about our bodies, weight loss, and wellness. Ozempic and other GLP-1 drugs like it ...

The FDA has declared the shortages as “resolved," removing the drugs from its shortage list. Boxes of Ozempic and Wegovy made by Novo Nordisk are seen at a pharmacy in London, March 8 ...

A fast-growing body of research signals potential health benefits of GLP-1s, the class of diabetes and weight-loss drugs known by names like Ozempic, beyond what they were initially approved to treat.

Ozempic (semaglutide) is a prescription drug used for certain conditions in people with type 2 diabetes. Ozempic is given as an injection under your skin. Ozempic can be prescribed for adults with ...

Shares of Novo Nordisk A/S were getting hit hard Monday, after the maker of Ozempic and Wegovy, the diabetes and obesity treatments, revealed data showing that its new weight-loss drug candidate ...

Some people have critiqued Ozempic (semaglutide)—a diabetes medication that can aid in weight loss—for the effects it has on the skin. Some people have reported "Ozempic face" and "Ozempic ...

The Food and Drug Administration ... a Super Bowl ad touting its weight loss product offerings, markets a compounded version of semaglutide, the active ingredient in Ozempic and Wegovy.